Journal article
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
Abstract
BACKGROUND: Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome.
METHODS: We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at …
Authors
Massie BM; Carson PE; McMurray JJ; Komajda M; McKelvie R; Zile MR; Anderson S; Donovan M; Iverson E; Staiger C
Journal
The New England Journal of Medicine, Vol. 359, No. 23, pp. 2456–2467
Publisher
Massachusetts Medical Society
Publication Date
December 4, 2008
DOI
10.1056/nejmoa0805450
ISSN
0028-4793
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Adrenergic beta-AntagonistsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsCardiovascular DiseasesDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHospitalizationHumansIrbesartanKaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsQuality of LifeStroke VolumeTetrazolesTreatment Failure